HomeWebinarsApplying AnteoBind™ Activated Estapor® Europium Microspheres for Development of Fluorescent Lateral Flow Immunoassays

Applying AnteoBind™ Activated Estapor® Europium Microspheres for Development of Fluorescent Lateral Flow Immunoassays


What Does it Cover?

In this technical presentation, we will provide you with an introduction to AnteoBind™ nanocoating technology and the use of AnteoBind™ activated Estapor® europium microspheres in lateral flow immunoassays.

We will discuss the common issues encountered in antibody conjugation, the detail of the alternative protein conjugation procedure using AnteoBind™ activated Estapor® europium microspheres, and the effects of physical characteristics (size, dispersity, surface charge) during the steps of conjugation and storage. We will also discuss the performance of conjugates in functional assay development for several popular biomarkers.

We will share best practices to troubleshoot antibody conjugation to AnteoBind™ activated Estapor® europium microspheres in assay development and the initial scale-up procedure. This information will be of interest to individuals involved in developing and validating lateral flow immunoassays and manufacturing process development.

What Will You Learn?

  • Industry trends for europium fluorescent lateral flow immunoassays
  • AnteoBind™ coordination chemistry – alternative to EDC conjugation and passive coupling
  • Performance of AnteoBind™ activated Estapor® europium microspheres
  • Selecting optimal conditions for your assay development
  • Best practices and troubleshooting applications

Who Should Attend?

  • Diagnostic Test Manufacturers
  • IVD Test Developers
  • Diagnostic Test End Users
  • Europium Microsphere-based Lateral Flow Assay Developers


Charlie Huang, B.Sc., M.Sc., Ph.D.

AnteoTech Ltd.

Head of Diagnostics and Life Science

Dr. Charlie Huang has more than 20 years of experience in multi-discipline environments. He is a full-spectrum industrial executive with experiences ranging from concept generation, upstream research, product design, development, manufacturing to commercialization.

He has demonstrated scientific expertise in the fields of life science, in vitro diagnostics, biotechnology and nanotechnology. He also has significant commercial expertise in business development, commercial strategy, project & team management, technology analysis & transfer, licensing, grants, and intellectual property.

Prior to joining Anteo, Charlie held senior management roles in several public listed healthcare and IVD companies including Panbio Ltd., Alere, Cellestis Ltd. and QIAGEN. He is working with the Anteo team to develop strategies, patents, products and services for industrial and life science applications and commercialization.

He holds a BSc in Life Science and an MSc in Molecular Engineering from NCHU. He obtained his PhD in Biochemistry and Molecular Biology from the University of Queensland. He has published scientific papers with strong impact factors and is co-inventor of many granted patents in the fields of novel diagnostics, medical devices, metal complex applications and energy.